2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.
Shilpa Gupta, MD, oncologist, Hematology and Medical Oncology, Cleveland Clinic, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.
The PARADIGM study used qualitative interviews with physicians to assess factors in treatment decision making and prescribing patterns for patients with locally advanced or metastatic urothelial cancer.
As a part of the PARADIGM study, approximately 150 oncologists answered the in-depth survey questionnaire, Gupta says. The study aimed to identify barriers that oncologists, specifically those in community practices, face when making treatment decisions, compared with those in academic centers, Gupta continues.
Investigators took a deeper dive into the data to identify treatment patterns for immunotherapy, frontline therapy, and other treatment types and settings, Gupta explains. Data presented at the 2022 ASCO Annual Meeting aimed to further classify physicians based on prescription volume and other factors, Gupta says. The survey also looked at the factors that influenced a physician to use a certain treatment, Gupta concludes.